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Summary: There are several safety issues in work zone areas due to decrease 
lane width, and presence of large equipment and on-site workers. The safety 
issues are compounded for drivers that are also drug impaired. In this study, we 
examine the driver performance of 18 commercial bus operators in a simulated 
environment while they are under the influence of a benzodiazepine drug 
(Triazolam). The findings show that those drivers under the influence of the drug 
had higher steering entropy and greater difficulty staying close to the intended 
travel lane when compared to those who were not under the influence of the drug. 
These wider travelling distances around work barrels, by those under the 
influence of Triazolam, could have a potential impact on the safety of nearby 
construction workers and heavy machine operators. 
 
INTRODUCTION 
 
According to Khattak et al (2002), there are approximately 700 traffic-related fatalities, and over 
75,000 injury and non-injury crashes per year in work zone areas in the US. The number of 
crashes in work zone areas are attributed to several factors, including the size of vehicle passing 
through the work area (Khattak and Targa, 2004), work zone configuration, speed limits through 
the zones, and environmental conditions (Li and Bai, 2008 and Harb et al., 2008). Studies using 
driving simulators are quite appropriate in examining issues related to work zones without 
increasing traffic congestion or decreasing safety (e.g, Morgan and Hancock, 2010, and Bella, 
2005). 
 
Work zone safety can also be impacted by drivers under the influence of drugs, whether 
prescription or illegal. Specific to prescription drug use, one type of drug widely used by drivers 
is short-acting benzodiazepines or non-benzodiazepine hypnotic drugs (i.e. sleep aids, sleeping 
pills) (van Laar and Volkerts, 1998). Based on data from the large truck crash causation study 
(US DOT, 2010), benzodiazepines were the second most used psychoactive drug among crash-
involved commercial drivers (with antidepressants being the first). One particular drug that has 
been used in the past is Triazolam (Halcion). Triazolam is a short acting benzodiazepine that has 
been used in patients who have difficulty in falling asleep (Roth et al., 1980) and in dental 
medicine to calm fearful patients (Milgram et al., 1994). This drug has been shown to increase 
crash risk by 13 fold during the first week of new prescription use when compared to those 
drivers not taking triazolam (Neutel, 1995). 
 
This current study examines the implications of this drug on driver performance as bus drivers 
traverse over a simulated work zone area. We hypothesize that drivers who have higher dosage 
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of Triazolam will have more difficult time traversing around a work zone area. The data used for 
this study comes from a larger study aimed at developing technology for measuring the impact of 
psychoactive prescription medications on the same-day and next-day driving performance of 
actively employed bus operators that hold a commercial driver license (CDL).  
 
METHODS 
 
Participants 
 
The participants were employed as a transit, coach or school bus driver around Iowa City, Iowa 
and recruited through newspaper ads, flyers at driving facilities, and through presentations as 
requested. Each participant completed three sessions over a 3-week period. Participants were 
excluded if they were currently using any other drugs known to enhance the effects of Triazolam 
(including grapefruit juice and birth control pills). Each session spanned 2 days (dosed and day-
after drives). There was also a day each of training, orientation, and physical examination. 
Drivers were also debriefed with a phone call that lasted approximately 1 hour. Hence, they were 
compensated $640 if they completed all drivers and tests. 
 
There were a total of 28 participants in the study but only 18 were used in this analysis because 
several participants did not complete all three dose trials. For ethical reasons, some drivers were 
removed from the study because their dosage level remained high on the day-after saliva 
specimen.  
 
Equipment 
 
A modern, high-fidelity bus driving simulator built by FAAC, Inc. and owned by the Paducah 
Area Transit System (PATS) was leased for this study. The FAAC bus is built on a Gillig Bus 
front end and has a 360-degree display through seven video-channels (3 front video projectors, 2 
side displays, 2 rear displays) and a complete set of bus controls. The simulator is housed in a 
large climate-controlled truck trailer purpose-build for the simulator with a 300 KV diesel 
electric generator for regulated electrical power for the simulator and computers. The simulator 
was driven from Paducah KY to Iowa City and parked in the parking lot of the National 
Advanced Driving Simulator (NADS) for the two-month duration of the experimental period. 
 
Procedure 
 
There were three experimental sessions spaced at least a week apart. Each experimental session 
consisted of five simulator drives (~ 10 minutes each) over a two-day period: four drives on day 
one and one drive the very next day. The drives on the first day of each session were 40 minutes 
apart and designed to measure current impairment through the known peak effect of the drug at 
approximately 90 minutes. The capsule for the day was ingested immediately following the 
completion of the first drive of the day, to provide a pre-dose measure of driver performance. 
Participants returned the next day to conduct the fifth drive of the session, to measure any carry-
over effects of the drug after a period of 10–14 hours including sleep. The next-day drive was a 
repetition of the pre-dose drive and no capsules were ingested. Each driver completed three 
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sessions of five drives. The analyses presented in this paper are focused only on those scenarios 
with a work-zone (i.e., 3rd and 4th drives on day 1). 
 
Subjects completed a short psychomotor test battery immediately before the first simulator drives 
on each test day. The battery was a subset of the ANAM (Automated Neuropsychological 
Assessment Metrics) (http://c-shop.ou.edu/anam4.htm). Psychomotor tests included a mood and 
sleepiness scale and six tests to measure reaction time, choice behavior, rotary tracking, math 
skills and short-term memory. The experimental protocol also included questionnaires after each 
session. Additionally, saliva samples were collected from each participant immediately following 
each experimental drive. The saliva samples were analyzed for Triazolam content to provide a 
surrogate measure for the instantaneous plazma levels of the active drug. 
 
As stated earlier, this study examined the work zone sections only which included two-lanes (or 
one-lane in each direction) and five barrels in a staggered position that purposely blocked the 
driver’s lane of travel, forcing drivers to maneuver around them. It is noted that due to 
constraints with the simulator, the work zone configurations were not designed to federal 
guidelines. The three work zone scenarios differed by the placement of the barrel and the length 
of the road segment. Scenario 1 also included a stop sign immediately preceding the work zone 
area (470 meters long). Scenario 2 was a straight road and drivers could see the barrels (376 m). 
Scenario 3 included a right hand turn immediately preceding the work zone area (792 m). 
Participants performed the experiment starting midday to late evening, with the majority of 
studies conducted in the afternoon due to driver work schedules. 
 
 
 
Figure 1. Example of barrel configuration 
 
Experimental design 
 
Triazolam (Halcion) was administered in a placebo-controlled, double-blind, randomized cross-
over design. On intake, each participant was randomized into one of the six groups representing 
the possible combinations of the experimental doses, placebo, 0.125 and 0.250, administered in a 
randomized order. The dose levels chosen are the most common dose levels prescribed for those 
suffering from sleeping problems. Each participant, over the three-week study period, received 
the 0.125 mg dose of Triazolam, the 0.250 mg, and the placebo dose in double-blind a 
randomized order. The sucrose placebo tablet, and the 0.125 and 0.250 mg capsules were 
administered in a standard drug capsule filled with sucrose to mask taste.  
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Dependent Measures 
 
The two dependent measures examined included the total driving distance of the driver’s path 
around the barrels and steering entropy. Total driving distance was examined as a surrogate for 
vehicle control. Participants that were cognitively impaired by Triazolam may not be able to 
control their vehicle with precision and any exaggerated lateral movement may equate to a 
longer distance traveled. 
 
Steering entropy is a measure that has been used to examine increased mental workload 
(Nakayama, 1999). A related measure based on the entropy calculation is the 90% interquartile 
range, , since entropy is centered normally distributed with mean=zero and standard 
deviation=. This measure () will give similar insights, compared to the traditional steering 
entropy, for drivers when a placebo baseline is not available across all drivers as is the case in 
this analysis. 
 
Explanatory Variables 
 
The dependent measure of interest was dose level and included three levels: placebo, 0.125 mg 
dose, and 0.250 mg dose of Triazolam. Covariates were also included given the potential that 
they may impact the outcome. These include the score for the simulator sickness questionnaire 
(SSQ) and the interaction between the SSQ score and the Triazolam saliva concentration, and 
dose administration order. A continuous variable for BMI score and the interaction of BMI with 
Triazolam Saliva concentration was also included as a covariate since studies show that those 
with larger body mass may have increased sensitivity to benzodiazepines which includes 
Triazolam (Greenblatt et. al, 1984 and Derry et al. 1995).   
 
The number of years as a commercial driver and the driver’s age were also considered as 
covariates. However, a moderately strong correlation existed between these variables and the 
BMI score so they were not included to avoid issues with multicollinearity (Farrar and Glauber, 
1967).  
 
RESULTS 
 
The 18 participants had a mean age of 24.56 years (sd= 6.48) and mean commercial driving 
experience of 2.28 years (sd= 1.90). There were 17 males and only one female. Due to this 
gender disparity, gender effects are not examined. The mean body mass index (BMI) of these 
participants was 26.72 (sd=6.24) with a range of 20 (considered normal) to 42 (considered 
obese). With three different driving scenarios and 18 participants, there was a total of 54 
individual drives examined in this analysis. 
 
Each participant had three observations representing each of the three work zone scenarios. 
Linear mixed effects models were used to estimate the possible effects of Triazolam on the 
participants’ total driving distance through the work zones and differences in steering entropy. 
This type of model allows for repeated observations to be taken into account. This model was 
fitted using the statistical package R (2.10.1) and the “nlme” package within that software.  
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A random intercept was estimated to account for the random effects unique to each driver. After 
fitting the model and observing the residuals vs. fitted values, the variable, driving distance, was 
also transformed by the log function to remove a slight mean-variance relationship in the 
residuals.  
 
Distance Travelled 
 
There was a significant difference between those who had received the placebo and those who 
did not (F(2, 28) = 5.09, p=0.01). More specifically, those who had the 0.125 mg dose of 
Triazolam, (t(28) = 2.87 ) travelled further distances than those who had received the placebo. 
Those with the 0.250 mg dose (t (28) = -1.01, p > 0.2 ) did not significantly differ from those 
who had the placebo. While those participants who received the 0.25mg dose did not, on 
average, significantly differ from those who had received the placebo, the variability over the 
distance traveled for the participants who received the 0.250mg was 1.5 times greater when 
compared to those who had received the placebo (see Figure 2 for an example).  
 
There was a difference in the physical configuration of each work zone area and this did impact 
the distance travelled (F (2, 28) = 27400, p < 0.001). Hence, a covariate was included to account 
for this effect. Dose order also impacted the distance traversed (F(5,11)=3.29, p=0.046) and was 
also included in the model. 
 
 
 
Figure 2. Driver’s paths under Placebo (top) and 0.250 (bottom) dosage 
(First Session, Third Drive) 
 
Steering Entropy 
 
Drivers with the 0.25 dose had an increase in steering entropy (F(2,28)=6.67, p=.004). The 
model was also adjusted for differences in the drive scenarios given that there was a higher 
steering entropy for the 2nd scenario (the short straight road) when compared to the 1st and 3rd 
drives. Those drivers with a higher BMI also had significantly lower steering entropy 
(F(1,11)=8.19, p<0.05). There were no other significant differences observed. 
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DISCUSSION 
 
Studies show that benzodiazepines impact psychomotor skills (Mintzer, 2002; Rush et al, 1993) 
and ultimately driving performance (Bramness et al., 2002). We had hypothesize that drivers 
who have higher dosage of Triazolam will have more difficult time traversing around a work 
zone area. Based on the results of the present study, drivers with 0.125 dose did travel further 
around the barrels than the drivers with the placebo, but interestingly, no difference in travel 
distance was observed for those with 0.25. Our data analysis examined the impact of dosage 
level within specific scenarios, but oftentimes, changes in behavior need to be observed over 
time. And drivers with 0.250 mg dose did show increased variability in their behavior while 
navigating the work zone area. This result and the significant increase in steering entropy 
observed under this treatment level are indications that there may be some cognitive impairment 
due to the Triazolam. 
 
Drivers under the influence may drive further away from the barrels than those who had a 
placebo because they are cautious (McMillan et al, 1989). However, they could also be having a 
more difficult time maintaining an efficient path around the barrels. Other studies do show 
greater variations in lane position for those drivers that are cognitively impaired (Ramaekers et 
al, 2000). Drivers who drive too far away from the barrels may also have a greater likelihood of 
colliding with ongoing construction. The increased demand associated with operating the vehicle 
while drug-impaired could potentially limit their ability to attend to other safety critical 
situations. 
 
However, the results do need to be interpreted cautiously as there were several study limitations. 
There was difficulty in retaining participants for the full study (3 weeks) and the power of the 
study was quite low. There were also very diverse drive scenarios (in terms of length and 
configurations) that prohibited a completely crossed design. The analysis did control for many 
variables statistically but it would have been beneficial to control for these experimentally. It is 
important to recognize that this was a proof of concept study only. The data for this analysis is 
part of a large study to assess safe driving performance under the influence of Triazolam. This 
specific study focused on drive performance in work zone areas but clearly, more research will 
be needed to identify specific scenarios where those drivers under the influence are at the 
greatest risk. 
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